Juvenile Idiopahtic ArthritisNCT07659223
Improving Outcomes for Juvenile Idiopathic Arthritis
A study testing The intervention was a one year support program JASP-1 in people with Juvenile Idiopahtic Arthritis, run by Region Stockholm at 1 site in Sweden.
Trial summary
Children and parents often experience uncertainty and stress when juvenile idiopathic arthritis (JIA) is first diagnosed, which creates a need for structured support. Juvenile Idiopathic Support Program (JASP-1) provide patient-and family centered support during the first year after diagnosis. Read more about this study
- Who is it for?
- Ages 0 to 16 years
- Conditions the study is for
- Juvenile Idiopahtic Arthritis
- What is being tested?
- The intervention was a one year support program JASP-1
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 116 participants
- Where
- 1 siteSweden
- Study dates
- 15 Aug 2019to 19 Feb 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 to 16 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- For the JASP-1: Diagnosed with JIA and have completed the JASP-1.
- For the control group: Diagnosed with JIA at the same clinic as above
Who cannot join
- No JIA diagnosis
- Change of diagnose during the year
- Do not understand or speak Swedish
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Improving Outcomes for Children Newly Diagnosed With Juvenile Idiopathic Arthritis Through a Structured Support Program (JASP-1) - A Longitudinal Register Study
Children and parents often experience uncertainty and stress when juvenile idiopathic arthritis (JIA) is first diagnosed, which creates a need for structured support. Juvenile Idiopathic Support Program (JASP-1) provide patient-and family centered support during the first year after diagnosis. However, little is known about how a support program like JASP-1 can influence outcomes. Therefore, this study aimed to longitudinally examine registry data from children who participated in JASP 1 and to compare the outcomes with registry data from a matched control group.
Read the detailed description
Methods: The study is a longitudinal register study with data from the Swedish Pediatric Rheumatology Quality Register (PedSRQ). Data included outcome measures from the child and/or the parents as well as clinical information's from the physicians.
- Conditions
- Juvenile Idiopahtic Arthritis
- Being tested
- The intervention was a one year support program JASP-1
- Keywords
- JIA, Support-program,, Register study
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
The intervention was a one year support program JASP-1Behavioural
Seven structured visits with a patient-and family-centered approach was used in the JASP-1 program, in which children newly diagnosed with JIA and their parents were invited to participate in.
| Study group | Role | What they receive |
|---|---|---|
| Participating in the Juvenile Arthritis Support Program (JASP-1) | Experimental | Children newly diagnosed with JIA and their parents were invited to participate in the intervention JASP-1. The intervention contains seven structured patient-and family centered visits the first year after JIA diagnose. With more visits close in the beginning. Receives: Behavioral: The intervention was a one year support program JASP-1 |
| Control group | No intervention | This arm is a control group consisting of 60 children matched in diagnose, gender and age with the ones in the intervention group. The children and parents in the control group did not receive any intervention. The data was collected from the PedSRQ register. |
What is being measured
The primary outcome is the main question the study is designed to answer.
CHAQ, Disabkids, Physicians global assessment
56 children received JASP-1and was on 3 timepoints compared with 60 children matched in disease, gender and age.The measures compared is CHAQ including pain, disease impact on overall well-being and school attendance, DISABKIDS, JADAS-71, Physicians global assessment, Number of active joints, Number of joint injections and Pharmacological treatment.
Outcomes at 12 months, were analyzed using the non parametric Mann-Whitney U test. For categorical variables differences were analyzed using the chi-square test to compare proportions. Repeated measurement ANOVA was used for calculating differences over time between the two groups. P value < 0.05 was considered statistically significant. Statistical analyses were performed using IBM SPSS Statistics for Windows, version 31.
Measured: For one year following JIA diagnosis
CHAQ
Childhood Health Assessment Queationnaire
Measured: Assessed several times during the first year after diagnosis. Values from 0-3
Disabkids
Health Related Quality of Life
Measured: Assessed at 3 timepoints during the first year, values between 0-100
Phycisians global assessment
Assessed at 3 timepoint during the first year after diagnosis. Valued on a VAS scale 0-10
Measured: During the first year after diagnosis
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jun 2026
- Study start15 Aug 2019
- Primary completion19 Feb 2026
- Study completion19 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Juvenile Idiopahtic ArthritisStudies of the same condition, open and under way.
- More trials run by Region StockholmThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Single group
- Model description
- The intervention JASP-1 is a support program consisting of seven structured visits the first year following JIA diagnosis
- Masking
- None (open label)
- Enrolment
- 116 participants (actual)
Sponsor and investigators
- Lead sponsor
- Region Stockholm
- Sponsor type
- Other government
- Collaborators
- Karolinska University Hospital, Karolinska Institutet
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07659223
- Sponsor's protocol ID
- K 2026-0525
- Status last verified
- May 2026
- First submitted
- 26 May 2026
- Last updated
- 22 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Improving Outcomes for Children Newly Diagnosed With Juvenile Idiopathic Arthritis Through a Structured Support Program (JASP-1) - A Longitudinal Register Study
- ClinicalTrials.gov ID
- NCT07659223
- Acronym / sponsor ID
- K 2026-0525
- Conditions
- Juvenile Idiopahtic Arthritis
- Keywords
- JIA, Support-program,, Register study
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 116 participants (actual)
- Lead sponsor
- Region StockholmOther government
- Collaborators
- Karolinska University Hospital, Karolinska Institutet
- Study start
- 15 Aug 2019 (actual)
- Primary completion
- 19 Feb 2026 (actual)
- Study completion
- 19 Feb 2026 (actual)
- First posted
- 22 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Children and parents often experience uncertainty and stress when juvenile idiopathic arthritis (JIA) is first diagnosed, which creates a need for structured support. Juvenile Idiopathic Support Program (JASP-1) provide patient-and family centered support during the first year after diagnosis. However, little is known about how a support program like JASP-1 can influence outcomes. Therefore, this study aimed to longitudinally examine registry data from children who participated in JASP 1 and to compare the outcomes with registry data from a matched control group.
Detailed description
Methods: The study is a longitudinal register study with data from the Swedish Pediatric Rheumatology Quality Register (PedSRQ). Data included outcome measures from the child and/or the parents as well as clinical information's from the physicians.
Study design
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- The intervention JASP-1 is a support program consisting of seven structured visits the first year following JIA diagnosis
| Arm | Type | Receives |
|---|---|---|
| Participating in the Juvenile Arthritis Support Program (JASP-1) | Experimental | Behavioral: The intervention was a one year support program JASP-1Children newly diagnosed with JIA and their parents were invited to participate in the intervention JASP-1. The intervention contains seven structured patient-and family centered visits the first year after JIA diagnose. With more visits close in the beginning. |
| Control group | No intervention | –This arm is a control group consisting of 60 children matched in diagnose, gender and age with the ones in the intervention group. The children and parents in the control group did not receive any intervention. The data was collected from the PedSRQ register. |
Who may qualify
- Ages
- 0 to 16 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (2 listed)
- For the JASP-1: Diagnosed with JIA and have completed the JASP-1.
- For the control group: Diagnosed with JIA at the same clinic as above
Key exclusion criteria (3 listed)
- No JIA diagnosis
- Change of diagnose during the year
- Do not understand or speak Swedish
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| The intervention was a one year support program JASP-1Seven structured visits with a patient-and family-centered approach was used in the JASP-1 program, in which children newly diagnosed with JIA and their parents were invited to participate in. | Behavioural | Participating in the Juvenile Arthritis Support Program (JASP-1) |
Primary outcome
CHAQ, Disabkids, Physicians global assessment
Time frame: For one year following JIA diagnosis
56 children received JASP-1and was on 3 timepoints compared with 60 children matched in disease, gender and age.The measures compared is CHAQ including pain, disease impact on overall well-being and school attendance, DISABKIDS, JADAS-71, Physicians global assessment, Number of active joints, Number of joint injections and Pharmacological treatment. Outcomes at 12 months, were analyzed using the non parametric Mann-Whitney U test. For categorical variables differences were analyzed using the chi-square test to compare proportions. Repeated measurement ANOVA was used for calculating differences over time between the two groups. P value < 0.05 was considered statistically significant. Statistical analyses were performed using IBM SPSS Statistics for Windows, version 31.
CHAQ
Time frame: Assessed several times during the first year after diagnosis. Values from 0-3
Childhood Health Assessment Queationnaire
Disabkids
Time frame: Assessed at 3 timepoints during the first year, values between 0-100
Health Related Quality of Life
Phycisians global assessment
Time frame: During the first year after diagnosis
Assessed at 3 timepoint during the first year after diagnosis. Valued on a VAS scale 0-10
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Juvenile Idiopahtic Arthritis
Enrolling by invitation
VR for Steroid Joint Injections - Feasibility
Acute Pain, Procedural Anxiety
Active, not recruiting
JIA Toolbox Feasibility Study
Juvenile Idiopahtic Arthritis
RecruitingObservational study
Cardiovascular Risk in Children With Chronic Conditions Study
Kidney Transplant, Familial Hypercholesterolaemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing The intervention was a one year support program JASP-1 in people with Juvenile Idiopahtic Arthritis, run by Region Stockholm at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
CHAQ, Disabkids, Physicians global assessment (time frame: For one year following JIA diagnosis). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2026.